Michael J. Fox Foundation Awards $468K for Protein Synthesis Inhibitor

Pennsylvania based QR Pharma has been awarded funds from the Michael J. Fox Foundation to further preclinical development of its orally available small molecule therapeutic, Posiphen. Although currently being tested in Parkinson’s disease models, Posiphen may also hold hope for ALS given the drug’s proposed mechanism of action.

Click here to read more.

Share this: